Evogene Ltd. - Ordinary Shares (EVGN): Price and Financial Metrics


Evogene Ltd. - Ordinary Shares (EVGN): $0.77

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EVGN to Watchlist
Sign Up

Industry: Agriculture


Ranked

of

in industry

EVGN POWR Grades


  • EVGN scores best on the Sentiment dimension, with a Sentiment rank ahead of 76.98% of US stocks.
  • The strongest trend for EVGN is in Quality, which has been heading down over the past 179 days.
  • EVGN's current lowest rank is in the Value metric (where it is better than 5.68% of US stocks).

EVGN Stock Summary

  • Evogene Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 7.63% of US listed stocks.
  • With a price/sales ratio of 60.65, Evogene Ltd has a higher such ratio than 96.59% of stocks in our set.
  • Revenue growth over the past 12 months for Evogene Ltd comes in at -28.35%, a number that bests only 5.79% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Evogene Ltd, a group of peers worth examining would be GSIT, SIMO, AGLE, CHRS, and MCRB.
  • EVGN's SEC filings can be seen here. And to visit Evogene Ltd's official web site, go to www.evogene.com.

EVGN Valuation Summary

  • In comparison to the median Healthcare stock, EVGN's EV/EBIT ratio is 108.87% lower, now standing at -2.6.
  • Over the past 106 months, EVGN's price/sales ratio has gone up 89.4.
  • EVGN's price/sales ratio has moved up 89.4 over the prior 106 months.

Below are key valuation metrics over time for EVGN.

Stock Date P/S P/B P/E EV/EBIT
EVGN 2021-08-31 102.7 1.5 -4.3 -2.6
EVGN 2021-08-30 89.6 1.3 -3.7 -2.0
EVGN 2021-08-27 94.4 1.4 -3.9 -2.2
EVGN 2021-08-26 92.0 1.4 -3.8 -2.1
EVGN 2021-08-25 95.8 1.4 -4.0 -2.3
EVGN 2021-08-24 92.3 1.4 -3.8 -2.2

EVGN Growth Metrics

    Its 4 year cash and equivalents growth rate is now at 693.92%.
  • Its 3 year net income to common stockholders growth rate is now at -11.09%.
  • The 2 year net income to common stockholders growth rate now stands at 3.49%.
Over the past 70 months, EVGN's revenue has gone down $9,514,000.

The table below shows EVGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.93 -24.839 -27.793
2021-09-30 0.97 -23.505 -28.544
2021-06-30 1.135 -22.087 -25.72
2021-06-30 1.135 -22.087 -25.72
2021-03-31 1.298 -18.727 -23.75
2020-12-31 1.04 -19.514 -23.374

EVGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EVGN has a Quality Grade of D, ranking ahead of 9.47% of graded US stocks.
  • EVGN's asset turnover comes in at 0.015 -- ranking 85th of 89 Chemicals stocks.
  • 500 - Internal server error

The table below shows EVGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.015 0.448 -2.136
2019-12-31 0.012 0.556 -0.546
2018-12-31 0.026 0.169 -0.317
2017-12-31 0.039 0.159 -0.253
2016-12-31 0.063 0.138 -0.203
2015-12-31 0.093 0.258 -0.146

EVGN Price Target

For more insight on analysts targets of EVGN, see our EVGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.5 (Moderate Buy)

EVGN Stock Price Chart Interactive Chart >

Price chart for EVGN

EVGN Price/Volume Stats

Current price $0.77 52-week high $3.58
Prev. close $0.77 52-week low $0.70
Day low $0.75 Volume 97,100
Day high $0.80 Avg. volume 258,558
50-day MA $0.91 Dividend yield N/A
200-day MA $1.61 Market Cap 19.83M

Evogene Ltd. - Ordinary Shares (EVGN) Company Bio


Evogene Ltd. operates as a plant genomics company that uses a technology infrastructure to enhance seed traits underlying crop productivity. The company was founded in 1999 and is based in Rehovot, Israel.


EVGN Latest News Stream


Event/Time News Detail
Loading, please wait...

EVGN Latest Social Stream


Loading social stream, please wait...

View Full EVGN Social Stream

Latest EVGN News From Around the Web

Below are the latest news stories about Evogene Ltd that investors may wish to consider to help them evaluate EVGN as an investment opportunity.

Medical-Grade Cannabis Developer Canonic Appoints Ex-SEO At Israeli Ministry Of Health To Its Board

Medical-grade cannabis developer Canonic Ltd. , and a wholly-owned subsidiary of Evogene Ltd. (NASDAQ: EVGN ), announced that professor Itamar Grotto will be joining its board of directors . Grotto, f ormer associate director general at the Israeli ministry of health , was responsible for the medicalization reform of cannabis in Israel and oversaw the Israeli medical cannabis agency . He was also the director of Israel''s public health services and a member of the executive board of the WHO , on behalf of the state of … Full story available on Benzinga.com

Benzinga | February 16, 2022

Canonic Announces Professor Itamar Grotto Joining its Board of Directors

Canonic Ltd., focused on the development of medical-grade cannabis products and a wholly-owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today that Professor Itamar Grotto will be joining its Board of Directors. Professor Grotto, former Associate Director General at the Israeli Ministry of Health, was responsible for the medicalization reform of Cannabis in Israel and oversaw the Israeli Medical Cannabis Agency. He was also the Director of Israel's Public Health Services

Yahoo | February 16, 2022

Computational Biology Company Evogene Confirms Earnings Results Release Date

Computational biology company Evogene Ltd . (NASDAQ: EVGN ) will release its financial results for the full year and fourth quarter of 2021 on March 10, 2022 . On the day of the announcement, the company''s management will host a conference call to discuss the results at 09:00 a.m. EST. Evogene established three unique … Full story available on Benzinga.com

Benzinga | February 15, 2022

Evogene Financial Results and Earnings Announcement Schedule for the Full Year and Fourth Quarter of 2021

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the full year and fourth quarter of 2021 on Thursday, March 10, 2022.

Yahoo | February 15, 2022

Evogene to Present at Aegis Virtual Conference

Evogene Ltd. (NASDAQ-GM: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments announced today that it will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 25th at 9:00 Eastern. The conference will span three days, starting on February 23rd until February 25th from 8:30AM until 5PM EST.

Yahoo | February 7, 2022

Read More 'EVGN' Stories Here

EVGN Price Returns

1-mo -11.55%
3-mo -40.77%
6-mo -57.92%
1-year -76.45%
3-year -53.33%
5-year -84.29%
YTD -53.05%
2021 -65.11%
2020 209.21%
2019 -23.23%
2018 -35.50%
2017 -39.80%

Continue Researching EVGN

Want to see what other sources are saying about Evogene Ltd's financials and stock price? Try the links below:

Evogene Ltd (EVGN) Stock Price | Nasdaq
Evogene Ltd (EVGN) Stock Quote, History and News - Yahoo Finance
Evogene Ltd (EVGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6054 seconds.